| Positron emission tomography in staging early lung cancer: a randomized trial. | |
| | |
MedLine Citation:
|
PMID: 19581636 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Among patients with early-stage non-small cell lung cancer (NSCLC), preoperative imaging tests are important in defining surgical candidates. OBJECTIVE: To assess whether whole-body positron emission tomography and computed tomography (PET-CT) plus cranial imaging correctly upstages cancer in more patients with NSCLC than does conventional staging plus cranial imaging. DESIGN: Randomized clinical trial with recruitment from June 2004 to August 2007. The centralized, computer-generated, variable block size randomization scheme was stratified by treatment center and cancer stage. Participants, health care providers, and outcome assessors were not blinded to imaging modality assignment. SETTING: 8 hospitals and 5 PET-CT centers in academic institutions. PATIENTS: Eligible patients were older than 18 years; had histologic or cytologic proof of stage I, II, or IIIA NSCLC on the basis of chest radiography and thoracic CT; and had a tumor considered to be resectable. INTERVENTION: PET-CT or conventional staging (abdominal CT and bone scan). All patients also had cranial imaging using CT or magnetic resonance imaging. MEASUREMENTS: The primary outcome was correct upstaging, thereby avoiding stage-inappropriate surgery. Secondary outcomes were incorrect upstaging and incorrect understaging. RESULTS: 170 patients were assigned to PET-CT and 167 to conventional staging. Eight patients (3 who had PET-CT and 5 who had conventional staging) did not have planned surgery. Disease was correctly upstaged in 23 of 167 PET-CT recipients and 11 of 162 conventional staging recipients (13.8% vs. 6.8%; difference, 7.0 percentage points [95% CI, 0.3 to 13.7 percentage points]), thereby sparing these patients from surgery. Disease was incorrectly upstaged in 8 PET-CT recipients and 1 conventional staging recipient (4.8% vs. 0.6%; difference, 4.2 percentage points [CI, 0.5 to 8.6 percentage points]), and it was incorrectly understaged in 25 and 48 patients, respectively (14.9% vs. 29.6%; difference, 14.7 percentage points [CI, 5.7 to 23.4 percentage points]). At 3 years, 52 patients who had PET-CT and 57 patients who had conventional staging had died. Limitation: The relatively small sample and the fact that some patients did not have planned surgery limited the ability to determine precise differences in clinical outcomes that were attributable to testing strategies. CONCLUSION: Preoperative staging with PET-CT and cranial imaging identifies more patients with mediastinal and extrathoracic disease than conventional staging, thereby sparing more patients from stage-inappropriate surgery, but the strategy also incorrectly upstaged disease in more patients. |
| | |
Authors:
|
Donna E Maziak; Gail E Darling; Richard I Inculet; Karen Y Gulenchyn; Albert A Driedger; Yee C Ung; John D Miller; Chu-Shu Gu; Kathryn J Cline; William K Evans; Mark N Levine |
Related Documents
:
|
14530496 - Pet scans in the staging of lymphoma: current status. 17895786 - Three-dimensional mdct gastrography compared with axial ct for the detection of early g... 19182496 - The clinical usefulness of (18)f-fdg pet/ct for the evaluation of lymph node metastasis... 16437396 - Additional value of hybrid pet/ct fusion imaging vs. conventional ct scan alone in the ... 19919856 - Pre-radiographic mri findings are associated with onset of knee symptoms: the most study. 21333776 - The incidentaloma: a medicolegal dilemma. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2009-07-06 |
Journal Detail:
|
Title: Annals of internal medicine Volume: 151 ISSN: 1539-3704 ISO Abbreviation: Ann. Intern. Med. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-08-18 Completed Date: 2009-08-25 Revised Date: 2009-12-17 |
Medline Journal Info:
|
Nlm Unique ID: 0372351 Medline TA: Ann Intern Med Country: United States |
Other Details:
|
Languages: eng Pagination: 221-8, W-48 Citation Subset: AIM; IM |
Affiliation:
|
Ontario Clinical Oncology Group, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00136890 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Brain / pathology, radiography Carcinoma, Non-Small-Cell Lung / diagnosis, pathology*, surgery Female Fluorodeoxyglucose F18 / diagnostic use Humans Lung Neoplasms / diagnosis, pathology*, surgery Magnetic Resonance Imaging Male Middle Aged Neoplasm Staging / methods* Positron-Emission Tomography* Radiopharmaceuticals / diagnostic use Survival Analysis Tomography, X-Ray Computed* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
| Comments/Corrections | |
Comment In:
|
Ann Intern Med. 2009 Dec 15;151(12):JC6-10
[PMID:
20008746
]
Ann Intern Med. 2009 Aug 18;151(4):279-80 [PMID: 19581638 ] |
Summary for patients in:
|
Ann Intern Med. 2009 Aug 18;151(4):I-21
[PMID:
19581637
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrilla...
Next Document: Dissecting an allosteric switch in caspase-7 using chemical and mutational probes.